vs
Leonardo DRS, Inc.（DRS）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是Leonardo DRS, Inc.的1.3倍（$1.4B vs $1.1B），瑞思迈净利率更高（27.6% vs 9.6%，领先18.0%），瑞思迈同比增速更快（11.0% vs 8.1%），Leonardo DRS, Inc.自由现金流更多（$376.0M vs $311.2M），过去两年Leonardo DRS, Inc.的营收复合增速更高（24.1% vs 9.0%）
莱昂纳多DRS公司是美国本土国防承包商，前身为DRS技术公司，曾于纽约证券交易所挂牌交易，2008年被莱昂纳多的前身芬梅卡尼卡收购，核心业务为向美国军方提供先进国防技术及配套系统产品。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
DRS vs RMD — 直观对比
营收规模更大
RMD
是对方的1.3倍
$1.1B
营收增速更快
RMD
高出2.9%
8.1%
净利率更高
RMD
高出18.0%
9.6%
自由现金流更多
DRS
多$64.8M
$311.2M
两年增速更快
DRS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $102.0M | $392.6M |
| 毛利率 | 25.4% | 61.8% |
| 营业利润率 | 11.9% | 34.6% |
| 净利率 | 9.6% | 27.6% |
| 营收同比 | 8.1% | 11.0% |
| 净利润同比 | 14.6% | 13.9% |
| 每股收益（稀释后） | $0.38 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DRSRMD
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $960.0M | $1.3B | ||
| Q2 25 | $829.0M | $1.3B | ||
| Q1 25 | $799.0M | $1.3B | ||
| Q4 24 | $981.0M | $1.3B | ||
| Q3 24 | $812.0M | $1.2B | ||
| Q2 24 | $753.0M | $1.2B | ||
| Q1 24 | $688.0M | $1.2B |
净利润DRSRMD
| Q4 25 | $102.0M | $392.6M | ||
| Q3 25 | $72.0M | $348.5M | ||
| Q2 25 | $54.0M | $379.7M | ||
| Q1 25 | $50.0M | $365.0M | ||
| Q4 24 | $89.0M | $344.6M | ||
| Q3 24 | $57.0M | $311.4M | ||
| Q2 24 | $38.0M | $292.2M | ||
| Q1 24 | $29.0M | $300.5M |
毛利率DRSRMD
| Q4 25 | 25.4% | 61.8% | ||
| Q3 25 | 23.1% | 61.5% | ||
| Q2 25 | 23.8% | 60.8% | ||
| Q1 25 | 22.7% | 59.3% | ||
| Q4 24 | 24.0% | 58.6% | ||
| Q3 24 | 22.0% | 58.6% | ||
| Q2 24 | 22.4% | 58.5% | ||
| Q1 24 | 22.2% | 57.9% |
营业利润率DRSRMD
| Q4 25 | 11.9% | 34.6% | ||
| Q3 25 | 9.7% | 33.4% | ||
| Q2 25 | 8.4% | 33.7% | ||
| Q1 25 | 7.4% | 33.0% | ||
| Q4 24 | 12.2% | 32.5% | ||
| Q3 24 | 9.2% | 31.6% | ||
| Q2 24 | 7.3% | 31.2% | ||
| Q1 24 | 6.3% | 31.3% |
净利率DRSRMD
| Q4 25 | 9.6% | 27.6% | ||
| Q3 25 | 7.5% | 26.1% | ||
| Q2 25 | 6.5% | 28.2% | ||
| Q1 25 | 6.3% | 28.3% | ||
| Q4 24 | 9.1% | 26.9% | ||
| Q3 24 | 7.0% | 25.4% | ||
| Q2 24 | 5.0% | 23.9% | ||
| Q1 24 | 4.2% | 25.1% |
每股收益（稀释后）DRSRMD
| Q4 25 | $0.38 | $2.68 | ||
| Q3 25 | $0.26 | $2.37 | ||
| Q2 25 | $0.20 | $2.58 | ||
| Q1 25 | $0.19 | $2.48 | ||
| Q4 24 | $0.34 | $2.34 | ||
| Q3 24 | $0.21 | $2.11 | ||
| Q2 24 | $0.14 | $1.97 | ||
| Q1 24 | $0.11 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $647.0M | $1.4B |
| 总债务越低越好 | $321.0M | $403.9M |
| 股东权益账面价值 | $2.7B | $6.3B |
| 总资产 | $4.5B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资DRSRMD
| Q4 25 | $647.0M | $1.4B | ||
| Q3 25 | $309.0M | $1.4B | ||
| Q2 25 | $278.0M | $1.2B | ||
| Q1 25 | $380.0M | $932.7M | ||
| Q4 24 | $598.0M | $521.9M | ||
| Q3 24 | $198.0M | $426.4M | ||
| Q2 24 | $149.0M | $238.4M | ||
| Q1 24 | $160.0M | $237.9M |
总债务DRSRMD
| Q4 25 | $321.0M | $403.9M | ||
| Q3 25 | $326.0M | $408.7M | ||
| Q2 25 | $331.0M | $658.4M | ||
| Q1 25 | $335.0M | $663.1M | ||
| Q4 24 | $340.0M | $662.9M | ||
| Q3 24 | $345.0M | $667.6M | ||
| Q2 24 | $351.0M | $697.3M | ||
| Q1 24 | $356.0M | $997.0M |
股东权益DRSRMD
| Q4 25 | $2.7B | $6.3B | ||
| Q3 25 | $2.6B | $6.1B | ||
| Q2 25 | $2.6B | $6.0B | ||
| Q1 25 | $2.6B | $5.5B | ||
| Q4 24 | $2.6B | $5.3B | ||
| Q3 24 | $2.5B | $5.2B | ||
| Q2 24 | $2.4B | $4.9B | ||
| Q1 24 | $2.4B | $4.6B |
总资产DRSRMD
| Q4 25 | $4.5B | $8.5B | ||
| Q3 25 | $4.2B | $8.3B | ||
| Q2 25 | $4.1B | $8.2B | ||
| Q1 25 | $4.1B | $7.6B | ||
| Q4 24 | $4.2B | $7.1B | ||
| Q3 24 | $3.9B | $7.2B | ||
| Q2 24 | $3.8B | $6.9B | ||
| Q1 24 | $3.8B | $6.8B |
负债/权益比DRSRMD
| Q4 25 | 0.12× | 0.06× | ||
| Q3 25 | 0.12× | 0.07× | ||
| Q2 25 | 0.13× | 0.11× | ||
| Q1 25 | 0.13× | 0.12× | ||
| Q4 24 | 0.13× | 0.13× | ||
| Q3 24 | 0.14× | 0.13× | ||
| Q2 24 | 0.15× | 0.14× | ||
| Q1 24 | 0.15× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $425.0M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $376.0M | $311.2M |
| 自由现金流率自由现金流/营收 | 35.5% | 21.9% |
| 资本支出强度资本支出/营收 | 4.6% | 2.0% |
| 现金转化率经营现金流/净利润 | 4.17× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $227.0M | $1.8B |
8季度趋势，按日历期对齐
经营现金流DRSRMD
| Q4 25 | $425.0M | $339.7M | ||
| Q3 25 | $107.0M | $457.3M | ||
| Q2 25 | $-28.0M | $538.8M | ||
| Q1 25 | $-138.0M | $578.7M | ||
| Q4 24 | $443.0M | $308.6M | ||
| Q3 24 | $59.0M | $325.5M | ||
| Q2 24 | $34.0M | $440.1M | ||
| Q1 24 | $-265.0M | $402.0M |
自由现金流DRSRMD
| Q4 25 | $376.0M | $311.2M | ||
| Q3 25 | $77.0M | $414.4M | ||
| Q2 25 | $-56.0M | $508.2M | ||
| Q1 25 | $-170.0M | $557.9M | ||
| Q4 24 | $414.0M | $288.0M | ||
| Q3 24 | $47.0M | $307.7M | ||
| Q2 24 | $0 | $415.2M | ||
| Q1 24 | $-275.0M | $380.8M |
自由现金流率DRSRMD
| Q4 25 | 35.5% | 21.9% | ||
| Q3 25 | 8.0% | 31.0% | ||
| Q2 25 | -6.8% | 37.7% | ||
| Q1 25 | -21.3% | 43.2% | ||
| Q4 24 | 42.2% | 22.5% | ||
| Q3 24 | 5.8% | 25.1% | ||
| Q2 24 | 0.0% | 33.9% | ||
| Q1 24 | -40.0% | 31.8% |
资本支出强度DRSRMD
| Q4 25 | 4.6% | 2.0% | ||
| Q3 25 | 3.1% | 3.2% | ||
| Q2 25 | 3.4% | 2.3% | ||
| Q1 25 | 4.0% | 1.6% | ||
| Q4 24 | 3.0% | 1.6% | ||
| Q3 24 | 1.5% | 1.5% | ||
| Q2 24 | 4.5% | 2.0% | ||
| Q1 24 | 1.5% | 1.8% |
现金转化率DRSRMD
| Q4 25 | 4.17× | 0.87× | ||
| Q3 25 | 1.49× | 1.31× | ||
| Q2 25 | -0.52× | 1.42× | ||
| Q1 25 | -2.76× | 1.59× | ||
| Q4 24 | 4.98× | 0.90× | ||
| Q3 24 | 1.04× | 1.05× | ||
| Q2 24 | 0.89× | 1.51× | ||
| Q1 24 | -9.14× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DRS
暂无分部数据
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
